Phaseline

Companies › Biokin (Shanghai) Biopharmaceutical

Biokin (Shanghai) Biopharmaceutical: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 2 Phase 1, 1 Phase 3, 1 Phase 2; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BL-M05D1
anti-CLDN18.2 antibody
CLDN18Phase 3Gastric Cancer; Locally Advanced or Metastatic Solid TumorsJun 2027
BL-M14D1–Phase 2Extensive-stage Small-cell Lung Cancer; Small Cell Lung CancerJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06349811BL-M05D1Phase 1Locally Advanced or Metastatic Solid TumorsOncologyJun 2027
NCT06505824BL-M14D1Phase 1Small Cell Lung CancerOncologyJun 2027
NCT07654400BL-M14D1Phase 2Extensive-stage Small-cell Lung CancerOncologyDec 2027
NCT07518147BL-M05D1Phase 3Gastric CancerOncologyDec 2029

Targets

CLDN18 (1)

Companies with the same targets

Astellas AstraZeneca RemeGen Shanghai Institute Of Biological Products Beijing Biotech Sichuan Kelun-Biotech Biopharmaceutical Transcenta Therapeutics (Hangzhou) Shanghai Hengrui Pharmaceutical Innovent Biologics (Suzhou) Antengene Biologics

Companies built like this

LaNova Medicines Zhejiang Hangzhou Sumgen Biotech Suzhou Immunofoco Biotechnology I-Mab Biopharma US FutureGen Biopharmaceutical (Beijing)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.